Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 5/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163801 | 0.84 | TDP1 (0.51) | MAPK8ALDH1A1KDRMAPK10 | |
| SCHEMBL7071615 | 0.83 | KMO (0.41) | KMOMAPK8MEN1KMT2A | |
| SCHEMBL8721027 | 0.80 | KMO (0.60) | KMOALDH1A1KDR | |
| SCHEMBL17673011 | 0.77 | ALKBH1 (0.55) | FFAR1MEN1KMT2ASRD5A2 | |
| SCHEMBL7041105 | 0.77 | HTT (0.50) | MAPK8ALDH1A1HTTLOXL2MEN1 | |
| SCHEMBL7041110 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HTTLOXL2MEN1KMT2A | |
| SCHEMBL2723992 | 0.77 | KMO (0.50) | FFAR1KMOALDH1A1 | |
| SCHEMBL4272019 | 0.74 | ALDH1A1 (0.47) | MAPK8ALDH1A1HTTLOXL2MEN1 | |
| SCHEMBL30748867 | 0.74 | AURKA (0.52) | MAPK8ALDH1A1KDRMEN1KMT2A | |
| SCHEMBL190518 | 0.74 | PLAAT3 (0.48) | ALDH1A1HTTLOXL2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292340-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-09-23 | — | — | US | disclosed |
| EP-3816163-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292340-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | LITAF, RIPK1, RIPK2 | FFAR1 497/4885KMO 4469/4885MAPK8 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.